|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 5,798,349
What Does the Patent Cover?
US Patent 5,798,349 protects a recombinant DNA-derived protein that is a human erythropoietin (EPO) analog. The patent's primary focus is on the production, composition, and therapeutic use of this EPO variant, specifically created through recombinant DNA technology.
Patent Overview
- Issue Date: August 25, 1998
- Inventors: Gunter Pauly, Stuart J. H. Williams, Heng H. Ngo
- Assignee: Amgen Inc.
- Field: Biotechnology, specifically the production of erythropoietin for treating anemia
Core Claims Breakdown
The patent contains 19 claims; key points include:
Claim 1: Recombinant Human Erythropoietin
- Scope: Covers a recombinant DNA-derived human erythropoietin comprising an amino acid sequence identical to natural EPO, with specific post-translational modifications.
- Implication: Encompasses monoclonal or polyclonal antibodies produced from this recombinant EPO.
Claim 2: Process for Producing Erythropoietin
- Scope: Describes a method of producing the protein through recombinant DNA expression in mammalian cells, such as Chinese hamster ovary (CHO) cells.
- Implication: Protects the process used in large-scale manufacturing.
Claim 3-4: Variants and Mutants
- Cover modifications or mutants of the native EPO, including amino acid substitutions or truncations designed to alter activity or stability.
Claim 10-13: Pharmaceutical Compositions
- Claim rights on formulations containing the recombinant EPO for therapeutic use, including dosing unit forms.
Claim 14-19: Use Claims
- Protects methods of treating anemia via administration of the recombinant EPO.
Key Elements of Claims
- Identity to natural EPO in amino acid sequence.
- Production in recombinant host cells.
- Use in treating anemia.
- Variants and modifications with specific amino acid changes.
Patent's Legal Scope and Limitations
- Excludes naturally occurring EPO from patentability. Patent protection is directed toward recombinant forms and their manufacturing processes.
- Claims are specific to mammalian cell expression systems, particularly CHO cells.
- Pharmacological claims focus on treatment of anemia, limiting protections to therapeutic methods.
Patent Landscape: Context and Competition
The patent landscape includes:
- Amgen’s Run: US 5,798,349 is part of a broad portfolio including foundational patents protecting recombinant EPO, notably US 4,703,008 (the original protein sequence patent filed in 1986).
- Key Competitors:
- Johnson & Johnson's Procrit: While J&J entered the market later, its rights intersect with patented formulations and production methods.
- Roche’s Mircera: Focused on long-acting EPO analogs, some claims overlap with those protected here, especially in variants and modified EPOs.
Patent Lifecycle
- Expiration expected around August 2018, with certain extensions depending on jurisdiction and patent term adjustments.
- Crucially, the patent influenced the landscape during its active term by blocking other recombinant EPO producers from using similar approaches.
Related Patents and IP
- Parent Patents: US 4,703,008—sequence patent for human erythropoietin.
- Subsequent Patents: Covering biosimilar modifications, long-acting formulations, and delivery devices.
Implications for Commercial and R&D Strategies
- Patent claims provide exclusivity covering production, variants, and uses of recombinant EPO.
- Companies seeking biosimilars or biosimilar-like products need to navigate around these claims or wait until patent expiry.
- The broad process and composition claims significantly impact generics and biosimilar pathways.
Summary
US 5,798,349 protects recombinant human erythropoietin's amino acid sequence, production methods, variants, and therapeutic uses. Its broad claims on the recombinant protein and methods made it a foundational patent in the biopharmaceutical manufacturing of EPO for over two decades.
Key Takeaways
- The patent's scope includes recombinant EPO identical to natural EPO, along with variants, formulations, and therapeutic applications.
- It relies heavily on recombinant DNA technology, particularly cell expression systems.
- Patent expiry around August 2018 opened the field to biosimilar entrants.
- The patent landscape is dense, with overlapping rights held by Amgen, J&J, and Roche, requiring careful navigation for biosimilar development.
- The patent's claims shape commercial legal protections in the EPO market for decades.
FAQs
1. What is the main innovation protected by US 5,798,349?
It protects a recombinant form of human erythropoietin produced via mammalian cells, and methods of manufacturing and using this protein therapeutically.
2. How does this patent influence biosimilar development?
It sets barriers in claiming recombinant production methods and variants, requiring biosimilar developers to design around its claims or wait until patent expiration.
3. Are modifications to EPO covered under this patent?
Yes, amino acid substitutions and variants fall within the scope, provided they meet the specific claim language.
4. When did the patent expire?
Expected expiration was August 2018, subject to patent term adjustments.
5. Can companies patent similar proteins today?
New proteins must differ significantly in sequence or modifications; otherwise, they risk infringement or invalidation for obviousness or lack of novelty.
References
- U.S. Patent and Trademark Office. Patent 5,798,349.
- European Patent Office. Erythropoietin patents overview.
- Lappin, T. R. (2010). Recombinant human erythropoietin. BioDrugs, 24(4), 285–293.
More… ↓
⤷ Start Trial
|
